Circulating Cell-Free CD Marker Phenotyping
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for identifying the CD marker phenotype of hematopoietic cells in pathologic conditions, such as leukemias and lymphomas, are limited as they require detection on intact cells, which can be invasive and not applicable for circulating free markers, hindering disease monitoring and treatment assessment.
Innovation Solution
A method involving the analysis of circulating cell-free CD markers in bodily fluids using specific antibodies to determine the CD phenotype, allowing for the identification of hematopoietic disorders, monitoring of disease progression, and tailoring treatment regimens by comparing marker levels in patient samples to normal controls.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If CD markers are detected on intact cells using flow cytometry, then measurement precision is improved, but ease of operation deteriorates due to invasive procedures and sample preparation requirements
Solution Approach 1:
The invention extracts CD markers from intact cells to detect them as circulating cell-free markers in bodily fluids. This extraction approach eliminates the need for invasive cell-based detection methods while maintaining the ability to identify CD phenotypes, thereby improving ease of operation without sacrificing measurement precision
Solution Approach 2:
The patent uses circulating cell-free CD markers as intermediaries to represent the CD phenotype of intact cells. These cell-free markers serve as mediators that carry phenotypic information without requiring direct analysis of intact cells, simplifying the detection process while preserving diagnostic accuracy
2Reliability
If traditional cell-based detection methods are used, then reliability of CD phenotype identification is improved, but productivity deteriorates due to inability to monitor circulating free markers
Solution Approach 1:
By extracting and detecting CD markers in their circulating cell-free form rather than requiring intact cells, the method enables continuous monitoring of disease progression and treatment response, significantly improving productivity while maintaining reliability through specific antibody-based detection
Solution Approach 2:
The invention enables continuous monitoring of CD marker levels in bodily fluids over time, allowing for ongoing disease surveillance and treatment assessment. This continuous detection capability improves productivity by eliminating the need for repeated invasive procedures while maintaining reliable phenotype identification
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables non-invasive identification and monitoring of hematopoietic disorders, improving diagnosis and prognosis, and facilitating treatment decisions by quantifying circulating CD markers in bodily fluids, thereby overcoming the limitations of traditional cell-based detection methods.
Implementation Method 1
assayed using antibodies specific to a panel of CD markers to determine a CD phenotype
Data Source
AI summary
The present invention provides methods of classifying cluster of differentiation (CD) marker phenotype for hematopoietic cancer cells using multiple circulating cell-free CD markers in bodily fluid. In other aspects, treatment and disease progression of particular hematopoietic cancers can be monitored by measuring the levels of CD and other markers in bodily fluids of a patient.